FDA Approval Alert: The Need-to-Know | Larotrectinib in Adult and Pediatric NTRK+ Solid Tumors

In April 2025, the FDA granted full approval status to the first-in-class TRK inhibitor larotrectinib as a treatment for pediatric and adult patients with solid tumors harboring NTRK gene fusions.

Data from the LOXO-TRK-14001, SCOUT, and NAVIGATE trials support the full approval of larotrectinib in NTRK gene fusion-positive tumors.
FDA OKs Larotrectinib in Adult and Pediatric NTRK+ Tumor Populations
Article
Apr 10, 2025 1:15 PM
Data from the LOXO-TRK-14001, SCOUT, and NAVIGATE trials support the full approval of larotrectinib in NTRK gene fusion-positive tumors.